Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

Table 2 FEV ₁ change from baseline at week 12 (day 84), ITT population

	VI 25 mcg OD (n = 101)	SAL 50 mcg BD (n = 100)	Placebo (n = 95)
LS mean change from baseline (ml)	359 (41.6)	283 (41.9)	289 (42.9)
Difference vs. placebo (ml)	70	-6	NA
95% CI	(-48 – 188)	(-124 – 113)
P-value	0.244	0.926

Values are weighted mean (SE) 0–24 hour FEV₁ (ml) unless otherwise stated.
ANCOVA model with covariates of baseline FEV₁, region, age, sex and treatment.
ANCOVA: analysis of covariates; BD: twice-daily; CI: confidence interval; FEV₁: forced expiratory volume in one second; ITT: intent-to-treat; LS: least squares; n: number of patients used in analysis; NA: not applicable; OD: once-daily; SAL: salmeterol; SE: standard error; VI: vilanterol.

ISSN: 1477-5751